Woodhouse Rebecca, Burton Jennifer K, Rana Namrata, Pang Yan Ling, Lister Jennie E, Siddiqi Najma
Department of Health Sciences, Hull York Medical School, University of York, Heslington, York, UK, York YO10 5DD.
Cochrane Database Syst Rev. 2019 Apr 23;4(4):CD009537. doi: 10.1002/14651858.CD009537.pub3.
Delirium is a common and distressing mental disorder. It is often caused by a combination of stressor events in susceptible people, particularly older people living with frailty and dementia. Adults living in institutional long-term care (LTC) are at particularly high risk of delirium. An episode of delirium increases risks of admission to hospital, development or worsening of dementia and death. Multicomponent interventions can reduce the incidence of delirium by a third in the hospital setting. However, it is currently unclear whether interventions to prevent delirium in LTC are effective. This is an update of a Cochrane Review first published in 2014.
To assess the effectiveness of interventions for preventing delirium in older people in institutional long-term care settings.
We searched ALOIS (www.medicine.ox.ac.uk/alois), the Cochrane Dementia and Cognitive Improvement Group (CDCIG) 's Specialised Register of dementia trials (dementia.cochrane.org/our-trials-register), to 27 February 2019. The search was sufficiently sensitive to identify all studies relating to delirium. We ran additional separate searches in the Cochrane Central Register of Controlled Trials (CENTRAL), major healthcare databases, trial registers and grey literature sources to ensure that the search was comprehensive.
We included randomised controlled trials (RCTs) and cluster-randomised controlled trials (cluster-RCTs) of single and multicomponent, non-pharmacological and pharmacological interventions for preventing delirium in older people (aged 65 years and over) in permanent LTC residence.
We used standard methodological procedures expected by Cochrane. Primary outcomes were prevalence, incidence and severity of delirium; and mortality. Secondary outcomes included falls, hospital admissions and other adverse events; cognitive function; new diagnoses of dementia; activities of daily living; quality of life; and cost-related outcomes. We used risk ratios (RRs) as measures of treatment effect for dichotomous outcomes, hazard ratios (HR) for time-to-event outcomes and mean difference (MD) for continuous outcomes. For each outcome, we assessed the overall certainty of the evidence using GRADE methods.
We included three trials with 3851 participants. All three were cluster-RCTs. Two of the trials were of complex, single-component, non-pharmacological interventions and one trial was a feasibility trial of a complex, multicomponent, non-pharmacological intervention. Risk of bias ratings were mixed across the three trials. Due to the heterogeneous nature of the interventions, we did not combine the results statistically, but produced a narrative summary.It was not possible to determine the effect of a hydration-based intervention on delirium incidence (RR 0.85, 95% confidence interval (CI) 0.18 to 4.00; 1 study, 98 participants; very low-certainty evidence downgraded for risk of bias and very serious imprecision). This study did not assess delirium prevalence, severity or mortality.The introduction of a computerised system to identify medications that may contribute to delirium risk and trigger a medication review was probably associated with a reduction in delirium incidence (12-month HR 0.42, CI 0.34 to 0.51; 1 study, 7311 participant-months; moderate-certainty evidence downgraded for risk of bias) but probably had little or no effect on mortality (HR 0.88, CI 0.66 to 1.17; 1 study, 9412 participant-months; moderate-certainty evidence downgraded for imprecision), hospital admissions (HR 0.89, CI 0.72 to 1.10; 1 study, 7599 participant-months; moderate-certainty evidence downgraded for imprecision) or falls (HR 1.03, CI 0.92 to 1.15; 1 study, 2275 participant-months; low-certainty evidence downgraded for imprecision and risk of bias). Delirium prevalence and severity were not assessed.In the enhanced educational intervention study, aimed at changing practice to address key delirium risk factors, it was not possible to determine the effect of the intervention on delirium incidence (RR 0.62, 95% CI 0.16 to 2.39; 1 study, 137 resident months; very low-certainty evidence downgraded for risk of bias and serious imprecision) or delirium prevalence (RR 0.57, 95% CI 0.15 to 2.19; 1 study, 160 participants; very low-certainty evidence downgraded for risk of bias and serious imprecision). There was probably little or no effect on mortality (RR 0.82, CI 0.50 to 1.34; 1 study, 215 participants; moderate-certainty evidence downgraded for imprecision). The intervention was probably associated with a reduction in hospital admissions (RR 0.67, CI 0.57 to 0.79; 1 study, 494 participants; moderate-certainty evidence downgraded due to indirectness).
AUTHORS' CONCLUSIONS: Our review identified limited evidence on interventions for preventing delirium in older people in LTC. A software-based intervention to identify medications that could contribute to delirium risk and trigger a pharmacist-led medication review, probably reduces incidence of delirium in older people in institutional LTC. This is based on one large RCT in the US and may not be practical in other countries or settings which do not have comparable information technology services available in care homes. In the educational intervention aimed at identifying risk factors for delirium and developing bespoke solutions within care homes, it was not possible to determine the effect of the intervention on delirium incidence, prevalence or mortality. This evidence is based on a small feasibility trial. Our review identified three ongoing trials of multicomponent delirium prevention interventions. We identified no trials of pharmacological agents. Future trials of multicomponent non-pharmacological delirium prevention interventions for older people in LTC are needed to help inform the provision of evidence-based care for this vulnerable group.
谵妄是一种常见且令人痛苦的精神障碍。它通常由易感人群,特别是患有虚弱和痴呆症的老年人中的应激源事件共同引发。居住在机构长期护理(LTC)机构中的成年人患谵妄的风险尤其高。谵妄发作会增加住院风险、痴呆症的发展或恶化以及死亡风险。多组分干预措施可将医院环境中谵妄的发生率降低三分之一。然而,目前尚不清楚在长期护理机构中预防谵妄的干预措施是否有效。这是对2014年首次发表的Cochrane系统评价的更新。
评估在机构长期护理环境中预防老年人谵妄的干预措施的有效性。
我们纳入了针对居住在永久性长期护理机构中的老年人(65岁及以上)预防谵妄的单组分和多组分、非药物和药物干预的随机对照试验(RCT)和整群随机对照试验(cluster-RCT)。
我们采用了Cochrane预期的标准方法程序。主要结局为谵妄的患病率、发病率和严重程度;以及死亡率。次要结局包括跌倒、住院、其他不良事件;认知功能;痴呆症的新诊断;日常生活活动;生活质量;以及与成本相关的结局。对于二分结局,我们使用风险比(RR)作为治疗效果的衡量指标;对于事件发生时间结局,使用风险比(HR);对于连续结局,使用平均差(MD)。对于每个结局,我们使用GRADE方法评估证据的总体确定性。
我们纳入了三项试验,共3851名参与者。所有三项均为整群随机对照试验。其中两项试验为复杂的单组分非药物干预,一项试验为复杂的多组分非药物干预的可行性试验。三项试验的偏倚风险评级不一。由于干预措施的异质性,我们未对结果进行统计学合并,而是进行了叙述性总结。无法确定基于补液的干预对谵妄发病率的影响(RR 0.85,95%置信区间(CI)0.18至4.00;1项研究,98名参与者;极低确定性证据因偏倚风险和非常严重的不精确性而降级)。该研究未评估谵妄患病率、严重程度或死亡率。引入计算机系统以识别可能导致谵妄风险的药物并触发药物审查,可能与谵妄发病率降低相关(12个月HR 0.42,CI 0.34至0.51;1项研究,7311参与者月;中等确定性证据因偏倚风险而降级),但可能对死亡率(HR 0.88,CI 0.66至1.17;1项研究,9412参与者月;中等确定性证据因不精确性而降级)、住院(HR 0.89,CI 0.72至1.10;1项研究,7599参与者月;中等确定性证据因不精确性而降级)或跌倒(HR 1.03,CI 0.92至1.15;1项研究,2275参与者月;低确定性证据因不精确性和偏倚风险而降级)影响很小或无影响。未评估谵妄患病率和严重程度。在旨在改变实践以解决关键谵妄风险因素的强化教育干预研究中,无法确定干预对谵妄发病率(RR 0.62,95%CI 0.16至2.39;1项研究,137居民月;极低确定性证据因偏倚风险和严重不精确性而降级)或谵妄患病率(RR 0.57,95%CI 0.15至2.19;1项研究,160名参与者;极低确定性证据因偏倚风险和严重不精确性而降级)的影响。对死亡率可能影响很小或无影响(RR 0.82,CI 0.50至1.34;1项研究,215名参与者;中等确定性证据因不精确性而降级)。该干预可能与住院率降低相关(RR 0.67,CI 0.57至0.79;1项研究,494名参与者;中等确定性证据因间接性而降级)。
我们的综述发现,关于在长期护理机构中预防老年人谵妄的干预措施的证据有限。一种基于软件的干预措施,用于识别可能导致谵妄风险的药物并触发由药剂师主导的药物审查,可能会降低机构长期护理机构中老年人谵妄的发生率。这是基于美国的一项大型随机对照试验,在其他没有类似养老院信息技术服务的国家或环境中可能不实用。在旨在识别谵妄风险因素并在养老院中制定定制解决方案进行的教育干预中,无法确定干预对谵妄发病率、患病率或死亡率的影响。该证据基于一项小型可行性试验。我们的综述确定了三项正在进行的多组分谵妄预防干预试验。我们未发现药物制剂的试验。未来需要针对长期护理机构中老年人的多组分非药物谵妄预防干预试验,以帮助为这一弱势群体提供循证护理。